{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:37:05Z","timestamp":1790642225522,"version":"4.1.0"},"reference-count":10,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title>\n            <jats:p>To study the post-marketing safety profile of ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) as experienced by retinal physicians in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>STUDY DESIGN\/MATERIALS AND METHODS:<\/jats:title>\n            <jats:p>Two thousand four hundred sixty-five retinal physicians were surveyed regarding their frequency of use of ocriplasmin and reports of ocular adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>There were 270 respondents (11%) who reported treating 1,056 eyes with ocriplasmin. The reports of adverse events (AE) were as follows: acute decline in visual acuity (16.95%), development of submacular fluid or serous retinal detachment (10.23%), dyschromatopsia (9.09%), progression of vitreomacular traction to macular hole (8.71%), development of retinal detachment (2.65%), development of retinal tear (1.99%), development of afferent pupillary defect (1.80%), electroretinography abnormalities (0.57%), crystalline lens instability (0.38%), and vasculitis (0.28%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Although the frequency of some ocular AEs reported in this study are comparable to those reported in the phase 3 registration trials, additional phase 4 safety studies are warranted to better understand the pathophysiology and clinical relevance of ocular AEs of ocriplasmin.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic>Ophthalmic Surg Imaging Lasers Retina<\/jats:italic>\n                . 2016;47:156\u2013160.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/23258160-20160126-09","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T21:03:54Z","timestamp":1455570234000},"page":"156-160","source":"Crossref","is-referenced-by-count":15,"title":["Post-Marketing Survey of Adverse Events Following Ocriplasmin"],"prefix":"10.3928","volume":"47","author":[{"given":"Sumit P.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"Jeng-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard F.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Matthew","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Prenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110823"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.94"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.8258"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.8142"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.278"},{"key":"e_1_3_1_7_2","article-title":"Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study","author":"Chatziralli I","year":"2015","unstructured":"Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol. May 2015. [Epub ahead of print]","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000519"},{"key":"e_1_3_1_9_2","volume-title":"Jetrea [package insert]","year":"2012","unstructured":"Jetrea [package insert]. Iselin, NJ: ThromboGenics; 2012."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000448"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000667"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/ophthalmology\/journals\/osli\/2016-2-47-2\/%7Bc3ba5920-955a-48d6-916f-66cb6b8b383b%7D\/post-marketing-survey-of-adverse-events-following-ocriplasmin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T06:17:45Z","timestamp":1683094665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20160126-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.3928\/23258160-20160126-09"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20160126-09","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}